If the role of FXII–FXI-driven coagulation in bacterial infections translates to humans, pharmacologic interference with FXII(a) and FXI(a) might increase risk of bacterial infection severity and pathogen dissemination leading to sepsis in treated patients, which should be monitored cautiously. This evidence concerns the gene F11 and bacterial infectious disease.